DVORACKOVA, E., P. PAVEK, B. KOVACOVA, Jitka RYCHLÍČKOVÁ, O. SUCHOPAR, M. HOJNY, J. D. TEBBENS and J. VLCEK. Is Computer-Assisted Aminoglycoside Dosing Managed by a Pharmacist a Safety Tool of Pharmacotherapy? Physiological research. Praha: Fyziologický ústav AV ČR, 2019, vol. 68, Suppl. 1, p. "S87"-"S96", 10 pp. ISSN 0862-8408. Available from: https://dx.doi.org/10.33549/physiolres.934329.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Is Computer-Assisted Aminoglycoside Dosing Managed by a Pharmacist a Safety Tool of Pharmacotherapy?
Authors DVORACKOVA, E. (203 Czech Republic, guarantor), P. PAVEK (203 Czech Republic), B. KOVACOVA (203 Czech Republic), Jitka RYCHLÍČKOVÁ (203 Czech Republic, belonging to the institution), O. SUCHOPAR (203 Czech Republic), M. HOJNY (203 Czech Republic), J. D. TEBBENS (203 Czech Republic) and J. VLCEK (203 Czech Republic).
Edition Physiological research, Praha, Fyziologický ústav AV ČR, 2019, 0862-8408.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30105 Physiology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 1.655
RIV identification code RIV/00216224:14110/19:00112619
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.33549/physiolres.934329
UT WoS 000499085100010
Keywords in English Therapeutic drug monitoring; Aminoglycosides; Pharmacist; Nephrotoxicity; Pharmacokinetics
Tags 14110516, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 11/5/2020 10:44.
Abstract
This pilot prospective study verified the hypothesis that use of computer-assisted therapeutic drug monitoring of aminoglycosides by pharmacists leads to better safety therapeutic outcomes and cost avoidance than only concentration measurement and dose adjustments based on a physician's experience. Two groups of patients were enrolled according to the technique of monitoring. Patients (Group 1, n=52) underwent monitoring by a pharmacist using pharmacokinetic software. In a control group (Group 2, n=11), plasma levels were measured but not interpreted by the pharmacist, only by physicians. No statistically significant differences were found between the groups in factors influenced by therapy. However, the results are not statistically significant but a comparison of the groups showed a clear trend towards safety and cost avoidance, thus supporting therapeutic drug monitoring. Safety limits were achieved in 76 % and 63 % of cases in Groups 1 and 2, respectively. More patients achieved both concentrations (peak and trough) with falling eGFR in Group 1. In present pilot study, the pharmacist improved the care of patients on aminoglycoside therapy. A larger study is needed to demonstrate statistically significantly improved safety and cost avoidance of aminoglycoside therapy monitoring by the pharmacist using pharmacokinetic software.
PrintDisplayed: 27/5/2024 18:47